genprowebdirectory
GEN Edge
News
Insights
Trends for 2021
Trends for 2020
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Resources
All
GEN Live
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Get GEN Edge
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
GEN Edge
CAR T-Cells
Caribou Rides RNA Wave with $115M Series C Financing
Drug Discovery
Delivering on a Promise: The Present and Future of Targeted Protein…
Gene Therapy
OXGENE Eyes Further Growth in Cell and Gene Therapy Services after…
Coronavirus
Breathe In: Theravance Reports Positive Phase II Data for JAK Inhibitor
Cancer
The Life Oncolytic, with Stephen Russell
News
News
Retinal Prostheses Poised to Provide Artificial Vision to the Blind
News
Huntington’s Disease Found to Slow Down Ribosomes and Protein Synthesis
Cellular Reprogramming
Scar-Forming Cells Switch to Producing New Neurons that Promote Functional Recovery…
OMICs
Fungi Influence Microbiome Metabolism of Processed Foods
interleukin
Halting Excessive Inflammation with New Way to Regulate Lymphocytes
Insights
All
Trends for 2021
Trends for 2020
Bioprocessing
Harvesting Plastic from Plants
Infectious Diseases
SARS-CoV-2 Under Surveillance
Cancer
Immune Cell Profiles Reveal Cancer’s Leading Indicators
Translational Medicine
Animal Models Offer Improved Translatability
A-Lists
A-Lists
Top 7 Best Selling COVID-19 Vaccines and Drugs of 2020
January 2021 Vol. 41 No. 1
Seven Biopharma Trends to Watch in 2021
A-Lists
Top 15 Best-Selling Drugs Launched in 2020
A-Lists
Top 50 NIH-Funded Institutions of 2020
July 2020 Vol. 40 No. 7
Top 10 Earners among Women Biopharma Executives
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Gene Therapy
Biogen Plans Gene Therapy Manufacturing Facility in NC
CAR T-Cells
Caribou Rides RNA Wave with $115M Series C Financing
Cellular Reprogramming
Scar-Forming Cells Switch to Producing New Neurons that Promote Functional Recovery…
OMICs
Fungi Influence Microbiome Metabolism of Processed Foods
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Resources
All
GEN Live
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Get GEN Edge
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Home
Genome Editing
Gene Therapy
Gene Therapy
Gene Therapy
Synthetic Biology
CRISPR-Cas9
Featured posts
Latest
Featured posts
Most popular
7 days popular
By review score
Random
On Demand Webinars
Improving Plasmid and Viral Vectors in Cell and Gene Therapy
Gene Therapy
Gene Therapy Molecular Switch May Control Dosing
Gene Therapy
Novel Gene Therapy for Duchenne Muscular Dystrophy Shows Promise
Gene Therapy
Going Viral: The Next Generation of AAV Vectors
Gene Therapy
Gene Therapy Cures Babies with “Bubble Boy” Disease
Gene Therapy
CRISPR and Beyond: Advances in Gene Therapy
Gene Therapy
Roche Expands into Gene Therapy with Planned $4.8B Acquisition of Spark...
Gene Therapy
AbbVie, Voyager Launch $1.5B+ Gene Therapy Collaboration Aimed at Parkinson’s, Other...
Gene Therapy
Gene Therapy Restores Congenital Deafness
Gene Therapy
Wilson among Co-Founders of Gene Therapy Developer Launched with $115.5M
Gene Therapy
J&J’s Janssen to Develop MeiraGTx’s Retinal Disease Gene Therapies
Gene Therapy
In $1.9B Alliance, Neurocrine to Develop Voyager Gene Therapies for Parkinson’s,...
Gene Therapy
Nerve Regeneration Pumped Up by Muscle Protein
Gene Therapy
Orchard Therapeutics Plans 3 Approval Submissions, In-House Manufacturing by 2021
Gene Therapy
Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo...
1
2
Page 1 of 2
Scroll Up
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
/* The alert message box */ .alert { padding: 20px; background-color: #ff9800; /* Red */ color: white; margin-bottom: 15px; } /* The close button */ .closebtn { margin-left: 15px; color: white; font-weight: bold; float: right; font-size: 22px; line-height: 20px; cursor: pointer; transition: 0.3s; } /* When moving the mouse over the close button */ .closebtn:hover { color: black; } .td_module_flex_2 .entry-title { font-size: 17px; line-height: 20px; }
![Spark Therapeutics saw its share price tumble about 30% in early-morning trading after it reported mixed preliminary data this morning from a Phase I/II trial of its hemophilia A gene therapy candidate SPK-8001. [Source: wildpixel/Getty Images]](https://www.genengnews.com/wp-content/uploads/2018/08/Dec7_2017_Getty_487489316_GeneTherapy_60019871441892139879144-265x198.jpg "Novel Gene Therapy for Duchenne Muscular Dystrophy Shows Promise")
